




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/543, 21/17		A1	(11) International Publication Number: WO 98/15831
			(43) International Publication Date: 16 April 1998 (16.04.98)
(21) International Application Number: PCT/CA97/00751 (22) International Filing Date: 9 October 1997 (09.10.97) (30) Priority Data: 08/727,998 10 October 1996 (10.10.96) US (71) Applicant (for all designated States except US): UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; IRC331-2194, Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): BROOKS, Donald, Elliott [CA/CA]; 3989 West 19th Avenue, Vancouver, British Columbia V6S 1C9 (CA). (74) Agents: VANDENHOFF, Deborah, G. et al.; Scott & Aylen, 60 Queen Street, Ottawa, Ontario K1P 5Y7 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: OPTICAL QUANTIFICATION OF ANALYTES IN MEMBRANES



(57) Abstract

Methods for measuring the amount of an analyte in a membrane, comprising applying to the membrane a clearing agent, are disclosed. The clearing agent can be an agent that has approximately the same refractive index as the membrane; alternatively, the clearing agent can be a dissolving agent, that dissolves the membrane. The analyte can be labelled to facilitate detection. Representative labels include fluorescent labels and detectable particles.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BD	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

OPTICAL QUANTIFICATION OF ANALYTES IN MEMBRANES

RELATED APPLICATIONS

This application is a Continuation-in-Part application
5 of U.S. serial number 08/727,998, the entire teachings of
which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Quantitative analysis of cells and analytes in fluid
10 samples, particularly bodily fluid samples, often provides
critical diagnostic and treatment information for
physicians and patients. Immunological testing methods
(Kennedy, D.M. and S.J. Challacombe, eds., ELISA and Other
Solid Phase Immunoassays: Theoretical and Practical
15 Aspects, John Wiley and Sons, Chichester (1988)), which
take advantage of the high specificity of the antigen-
antibody reaction, provide one approach to measurement of
analytes. Immunoassays which provide a quantitative
measurement of the amount of an analyte in a sample often
20 use complex, multistep procedures and expensive analyzers
available only in a laboratory setting.
Immunochematographic assays, such as those described in GB
2,204,398A; U.S. patents 5,096,837, 5,238,652, and
5,266,497; Birnbaum, S. et al., *Analytical Biochem.*
25 206:168-171 (1992); Roberts, M.A. and R.A. Durst,
Analytical Chem. 67:482-491 (1995); and Klimov, A.D. et
al., *Clinical Chem.* 41:1360 (1995), are simpler.
Immunochematographic assays rely for their interpretation
on the observation of colored reaction products, usually
30 colored particles, in a particular region of a membrane.
To obtain a quantitative measure of the amount of an
analyte detected in an immunochematographic assay, the
amount of colored particles is analyzed.

Measurement by optical means of the amount of particles accumulated in one or more regions of a membrane is usually performed by reflectometry or densitometry. In these techniques, a light beam is either reflected or transmitted through the colored portion of the membrane, and the light intensity reaching a detector is measured. Other methods include obtaining, with a video camera, the image of the membrane illuminated with transmitted or reflected light, and performing image analysis on a frame of the video record. Although image analysis software allows considerable manipulation of the image to optimize sensitivity in detection of the particles, these methods suffer from light scattering by the membrane fibers in which the particles are imbedded. The multiple scattering that results obscures the optical signal produced by the particles and dramatically increases the noise level in the measurement.

SUMMARY OF THE INVENTION

The current invention pertains to methods for quantifying the amount of an analyte in a membrane, in which the membrane is rendered transparent by a clearing agent, and the amount of analyte is measured using an optical means. The membrane can be rendered transparent by wetting the membrane with a clearing agent that has a refractive index (n_D) that is approximately equal to the refractive index of the substance from which the membrane is made. For example, a nitrocellulose membrane can be cleared with polyvinylpyrrolidone, polyethyleneimine, or benzyl alcohol. Alternatively, the membrane is rendered transparent by applying to the membrane a dissolving agent that dissolves the membrane to form a clear background. For example, a nitrocellulose membrane can be cleared using polyethylene glycol as a dissolving agent. The amount of analyte in the membrane is measured using an optical

sensor, such as a sensor that measures fluorescence or light scattering. The analyte can be labelled with a fluorescent label or with detectable particles, such as inorganic particles, organic molecules, liposomes, or organic polymer latex particles, in order to facilitate quantification of the analyte.

Rendering the membrane transparent facilitates detection of the analyte and enhances accuracy and sensitivity of the quantification of the particles, by eliminating or minimizing light scattering by the membrane fibers, and thereby decreasing the noise level caused by background interference in the measurement. The methods are simple, rapid, and can be used for a wide variety of analytes and membranes.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 is a graphic representation of the relative signal intensity for various concentrations of latex particles in cleared and in uncleared nitrocellulose membranes.

DETAILED DESCRIPTION OF THE INVENTION

The current invention pertains to methods of optically detecting and quantifying analytes in a membrane. As described herein, the accuracy and sensitivity of quantification of analyte in a membrane with a light scattering or fluorescence means is enhanced by rendering the membrane transparent. The term, "analyte," as used herein, refers to the molecule, compound, particle, cell fragment, cell, or biological entity for which the amount will be quantified. Examples of analytes include proteins, such as hormones or enzymes; glycoproteins; peptides; small molecules; polysaccharides; antibodies; nucleic acids; drugs, including drugs of abuse; toxins; inorganic particles such as colloidal gold particles; viruses or

virus particles; bacteria; whole cells; portions of bacteria or cells; and other compounds. More than one analyte can be quantified. Also or in addition, a control analyte can be quantified.

5 To perform the methods of the invention, a membrane of interest is provided, having therein the analyte to be quantified (if any is present). The membrane is made of a substance having the capability to be rendered transparent. The membrane can be translucent (i.e., is capable of
10 allowing diffuse light to pass through), or opaque (i.e., incapable of allowing light to pass through). Examples of membrane substances include: cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and
15 polyethersulfone. In a preferred embodiment, the membrane is made of cellulose nitrate, cellulose acetate, glass fiber, or nylon. The membrane can consist of more than one substance: for example, it may consist of nitrocellulose with a Mylar™ backing. If the membrane is made of more
20 than one substance, each substance should either be transparent, or be capable of being rendered transparent.

Analyte "in" or "held in" the membrane includes analyte present on the surface of the membrane, as well as analyte within the substance of the membrane. The analyte
25 can be held in the membrane by adhering to the membrane (e.g., to membrane fibers). Alternatively, the analyte can be trapped within pores or interstices of the membrane. The analyte can also be held in the membrane by applying the analyte in a fluid to the membrane, and then allowing
30 the membrane to dry.

In another embodiment, the analyte is held in the membrane by binding of the analyte to an analyte-binding agent which is immobilized in the membrane. An analyte is
35 "bound" to an analyte-binding agent if it is physically or chemically attached to, adhered to, or associated with, the

analyte-binding agent. Analyte-binding agents include antibodies specific for the analyte, receptors that specifically bind to the analyte, genetically engineered binding reagents, bacterial or viral adhesions, aptimers, chelators, binding reagents generated by combinatorial chemistry, or other molecules that bind to the analyte. For example, the analyte can be bound to the membrane by interaction of the analyte with an antibody that is immobilized in the membrane. The term, "antibody," as used herein, encompasses both polyclonal and monoclonal antibodies, as well as mixtures of more than one antibody reactive with an epitope of interest (e.g., a cocktail of different types of monoclonal antibodies reactive with the peptide). The term antibody is further intended to encompass whole antibodies and/or biologically functional fragments thereof, chimeric antibodies comprising portions from more than one species, humanized antibodies, human-like antibodies, surfaced antibodies, and bifunctional antibodies. Biologically functional antibody fragments which can be used are those fragments sufficient for binding of the antibody fragment to the analyte of interest.

The analyte can be labelled to facilitate detection. Examples of such labels include luminescent labels; phosphorescent labels; colorimetric labels, such as dyes; or fluorescent labels. Representative fluorescent labels include fluorescein, fluorescein isothiocyanate (FITC), rhodamine, tetramethyl rhodamine isothiocyanate (TRITC), Texas red, phycoerythrin, or other fluorochromes. The analyte can be directly labelled, such as by attachment of a fluorochrome to the analyte. Alternatively, the analyte can be indirectly labelled, such as by labelling of the analyte with a reporter molecule (e.g., biotin, digoxigenin), which can be recognized by a reporter-binding molecule (e.g., avidin, streptavidin, or digoxigenin

antibody). The reporter-binding molecule is in turn attached to a fluorescent label. The analyte can also be labelled with an antibody that specifically binds to the analyte. The analyte-binding antibody can be conjugated to
5 a fluorochrome. Alternatively, it can be labelled through the use of a secondary antibody conjugated to a fluorochrome, where the secondary antibody recognizes and is specific for the primary, analyte-binding antibody; or through the use of streptavidin-biotin conjugates, where
10 the primary, analyte-binding antibody is recognized by a biotinylated secondary antibody, which interacts with a streptavidin fluorochrome.

In another embodiment, the analyte can be labelled with a detectable particle. A "detectable particle," as
15 used herein, is a particle which can be detected using an optical sensor.

An "optical sensor" is a sensor that detects electromagnetic radiation method based on the measurement or estimation of a characteristic of light, such as light
20 intensity, reflection, refraction, polarization, fluorescence lifetime, or light of a particular wavelength. Examples are fluorescence intensity measurements, light scattering intensity measurements, analysis of images from optical or fluorescence microscopy, densitometry, and
25 reflectometry.

The analyte is bound to the detectable particle in an appropriate manner, such as by binding of the analyte to an analyte-specific antibody coated on the surface of the particle. Examples of detectable particles include
30 colloidal gold particles; colloidal sulphur particles; colloidal selenium particles; colloidal barium sulfate particles; colloidal iron sulfate particles; metal iodate particles; silver halide particles; silica particles; colloidal metal (hydrous) oxide particles; colloidal metal
35 sulfide particles; colloidal lead selenide particles;

-7-

colloidal cadmium selenide particles; colloidal metal phosphate particles; colloidal metal ferrite particles; any of the above-mentioned colloidal particles coated with organic or inorganic layers; protein or peptide molecules; liposomes; or organic polymer latex particles. In a preferred embodiment, the particles are polystyrene latex beads, and particularly, polystyrene latex beads that have been prepared in the absence of surfactant, such as surfactant-free Superactive uniform Aldehyde/Sulfate Latexes (Interfacial Dynamics Corp., Portland, OR). Detectable particles can be additionally labelled to enhance detection: for example, a liposome or a latex bead can be dyed or can be made to incorporate fluorochromes.

The type of label for the analyte will vary, depending on the analyte, the membrane, method of detection used, the results sought, and other factors. If the particles themselves are not transparent (i.e., if the particles can be detected using an optical sensor), it may not be necessary to label the particles.

To conduct the assays of the invention, a clearing agent is used. The clearing agent is an agent that causes the membrane to become transparent; that does not dissolve the analyte or interfere with any label used; and that does not significantly displace the analyte. The term, "transparent," as used herein, indicates that light passes through the membrane with little or no scattering caused by the substance of the membrane.

In one embodiment, the clearing agent is within the membrane itself. For example, the clearing agent can be a solid substance that is incorporated into the membrane. For example, if the membrane is nitrocellulose, the clearing agent can be polyethylene glycol, preferably polyethylene glycol having a molecular weight of 1,000. The clearing agent is activated at an appropriate time using an appropriate means for activation. For example, if

the clearing agent is a solid agent that liquifies at a certain temperature, and that clears the membrane when it is liquified, the clearing agent can be activated by heating the membrane containing the clearing agent to an appropriate temperature. When the clearing agent liquifies, it clears the membrane.

In another embodiment, the clearing agent is applied onto the membrane to be assayed for the quantity of analyte. The clearing agent is applied to the membrane using standard techniques known to those of ordinary skill in the art. For example, clearing agent can be coated, sprayed, dropped, wicked, sprinkled, or blotted into the membrane. Alternatively, the membrane can be briefly immersed in the clearing agent. In a preferred embodiment, the clearing agent is a liquid, because of the ease of application of a liquid to the membrane.

In one embodiment, the clearing agent is an agent that, when it is a liquid, has approximately the same refractive index as the membrane. The intensity of scattered light depends on the square of the difference in refractive index between the scattering object and the medium in which it is immersed. Therefore, an agent having approximately the same refractive index as the membrane will eliminate interference. For example, the refractive index of nitrocellulose is $n_D = 1.538$ (the subscript refers to the sodium D line, the wavelength of which is 589 nm, which is a common wavelength at which to measure the refractive index). Therefore, a clearing agent for nitrocellulose has a refractive index between approximately 1.530-1.545, and preferably between approximately 1.535-1.540, and more preferably approximately 1.538. Representative clearing agents for nitrocellulose include polyvinylpyrrolidone ($n_D = 1.51$ -1.54, depending on molecular weight); polyethyleneimine (PEI; $n_D = 1.52$ -1.53, depending on molecular weight) and benzyl alcohol ($n_D =$

1.538). In a preferred embodiment, PEI having a molecular weight of approximately 700 is used as a clearing agent for a nitrocellulose membrane. Other clearing agents include mixtures of water and PEI for glass fiber membranes, the exact composition determined to be that which matches the index of refraction of the glass ($n_D = 1.46-1.52$, depending on type). If the clearing agent is an agent that has approximately the same refractive index as the membrane, and if the means for detection of the analyte is light scattering, then any label used for the analyte should have a refractive index that is different from that of the clearing agent and the membrane. If a different label is used (such as fluorescence), then it is not necessary for the clearing agent to have a refractive index different from that of the label.

In a second embodiment of the invention, the clearing agent is a dissolving agent. A "dissolving agent," as described herein, is an agent that dissolves the membrane into a clear substance. The dissolving agent is viscous enough to dissolve the membrane, without significantly displacing the analyte from the position it held prior to application or activation of the dissolving agent. For example, nitrocellulose is dissolved by low molecular weight polymers such as polyethylene glycols (PEGs). A single polymer, or a mixture of different polymers, can be used as the clearing agent.

The membrane is maintained under conditions sufficient to allow clearing of the membrane. The term, "clearing" of the membrane, indicates that the membrane becomes transparent. Clearing of the membrane, as described herein, also refers to dissolving the membrane to a clear (transparent) substance.

For example, if the clearing agent is an agent within the membrane or applied to the membrane that, when liquefied, clears the membrane, the membrane is maintained

at an appropriate temperature to liquefy the clearing agent. In another example, enough time should be allowed to elapse to allow clearing to proceed. The clearing time varies from seconds to hours, depending on the viscosity of the agent and the membrane characteristics. Some agents act effectively instantaneously upon application or activation; others require time to clear the membrane.

Following clearing of the membrane, the amount of the analyte can be quantified by an appropriate sensor that detects electromagnetic radiation, such as an optical sensor. For example, if the analyte is labelled with a fluorescent label, the amount of analyte can be quantified by measuring fluorescence intensity. The quantity of analyte can be calculated based on the strength of the fluorescence signal. Alternatively, if the analyte is detectable without a label, or if the analyte is labelled using a detectable particle, the amount of analyte can be quantified by measuring the light scattering at one or more angles from the incident light direction

A representative optical sensor, which could be used for a wide range of different types of membranes and analytes, could include the following: a filter or other means to select an emission wavelength for fluorescence measurements; a single or multichannel photodetector device to measure light intensity; a light source for excitation of fluorescence or measurement of reflectance; a collimated light source for forward light scattering measurement; and/or a diffuse light source for transmittance measurement of concentrated analyte. The light source and/or the filter could be selected for the appropriate mode of measurement desired.

More than one type of analyte can be quantified at the same time: for example, analytes having different fluorescent labels can be detected by measuring the fluorescent intensity of each label. Alternatively, one

analyte can be quantified by fluorescence, and another by measuring light scattering. A control analyte can also be used and quantified.

The methods of the invention permit highly sensitive
5 detection and quantification of analyte in a membrane. The
methods are particularly useful for quantitative
immunochromatographic assays to assess the quantity of
analytes in a fluid sample, using a Rapid Antigen
Measurement Platform (RAMP™) apparatus. In such a
10 quantitative immunochromatographic assay, a RAMP™
apparatus is used. In one embodiment, the apparatus
includes a membrane strip made of cellulose nitrate; the
membrane strip has an application point, a detection zone,
and a contact region between the application point and the
15 detection zone. Imbedded in the contact region is a
population of particles, such as colloidal metal particles,
organic molecules, liposomes, or organic polymer latex
particles, coated with an antibody to the analyte of
interest. A detection reagent, such as antibody to the
20 analyte of interest, or the analyte of interest itself, is
immobilized in the detection zone. A fluid sample to be
assayed for the analyte of interest is applied to the
application point, and the apparatus is maintained under
conditions which allow capillary action of fluid to
25 transport analyte of interest through the membrane strip to
the contact region, so that when analyte reaches the
contact region, it binds to the antibody-coated particles.
The antibody-coated particles are mobilized by the fluid
and move by capillary action through the membrane to the
30 detection zone. In the detection zone, the detection
reagent interacts with the antibody-coated particles,
leading to arrest of analyte-bound antibody-coated
particles in the detection zone. The amount of analyte-
bound antibody-coated particles in the detection zone is
35 quantified. The amount of analyte in the fluid sample can

be calculated, based on amount of analyte-bound antibody-coated particles in the detection zone. More detailed teachings concerning quantitative immunochromatographic assays are described in U.S. patent application serial number 08/625,048, entitled "Quantitative Immunochromatographic Assay", filed on March 29, 1996, the entire teachings of which are incorporated herein by reference. The accuracy and sensitivity of this quantitative immunochromatographic assay is greatly enhanced by the methods described herein. After arrest of analyte-bound antibody-coated particles in the detection zone of the membrane, the clearing agent is applied to the RAMP™ apparatus membrane, and apparatus is maintained under conditions sufficient to allow clearing of the membrane. Quantification of the analyte-bound antibody-coated particles in the detection zone is enhanced approximately 20-fold by clearing of the membrane.

The invention is further illustrated by the following Examples.

Example 1: Quantitative Analysis of Latex Particles Imbedded in a Nitrocellulose Membrane

A video image analysis system utilizing a DVC 10 bit digital CCD camera mounted on a Wild APOZOOM lens system, an Imaging Technology IC-PCI-2.0 frame grabber and OPTIMAS 5.2 image analysis software on a 120 MHZ Pentium PC was used to quantitate the signal produced by a population of latex particles imbedded in a Sartorius NC 5 nitrocellulose membrane having a transparent Mylar™ backing. Samples of latex particles, stained navy blue and having a diameter of 0.53 μm , were coated with bovine serum albumin (BSA) to a surface concentration of approximately $3 \times 10^{-4} \text{ mg/cm}^2$ and allowed to travel approximately three cm by capillary action in 0.05 M tris-HCl buffer to a detection zone of the nitrocellulose membrane. The detection zone (the area of

-13-

the membrane which was analyzed to quantify the analyte) had been prepared by applying 3 X 5 μ l of a polyclonal antibody preparation of rabbit anti-BSA IgG to the membrane, blocking with 1% polyvinyl alcohol (MW 15,000) for approximately four hours, then washing three times with distilled water. The latex concentration was varied from 1.6×10^{-5} g/ml to 1.3×10^{-3} g/ml, and 5 μ l of latex suspension was applied to the membrane at the opposite end from the detection zone. No latex was detected beyond the detection zone in any membrane upon completion of migration in the membrane, thus implying that essentially all of the latex had been arrested in the detection zone. Duplicate membrane strips, each pair having a different concentration of latex particles, were prepared.

One of each set was imaged with transmitted light without the use of a clearing agent, while the second was treated with a drop of PEG 600 over the detection zone before analysis. For the untreated membranes, the analysis was performed with the video camera on the vertical axis above the membrane and the light supplied by a diffuse source below the membrane and aimed directly at the camera. The focussed image of the detection zone produced by the transmitted light was then analyzed.

For the membranes treated with a clearing agent, the analysis was performed by recording and analyzing the image obtained when the membrane was illuminated from below with a collimated beam oriented at an angle of about 30 degrees from the vertical, with the camera again located above the sample on the vertical axis. In this case the background in the focussed image of the detection zone appeared dark, with the arrested latex forming a bright band as a result of the forward scattered light collected by the camera.

In each case, the image was optimized by background subtraction, and the final image was integrated to provide

the integrated pixel intensity representing the signal from the latex particles.

Results are shown in Figure 1, where the relative integrated signal intensity is plotted as a function of the relative number of latex particles applied to each membrane. The results demonstrate a large increase in signal provided by the cleared membrane relative to the uncleared membrane.

10 Example 2 Demonstration of Reduction in Background with
Fluorescence

A breadboard reader equipped with filters to allow efficient detection of fluorescence in the appropriate regions was used. A test line of 1 mg/ml of anti-myoglobin monoclonal antibody at 1 microliter per cm was deposited on Sartorius CN 8 micron mylar-backed nitrocellulose membranes, and the membranes were allowed to dry. After drying, the membranes were blocked with 1% w/v polyvinyl alcohol (MW approximately 15,000) and then either left untreated, or cleared with 50 microliters of PEG 400. The background fluorescence was measured at the deposited protein line. The wavelengths used were: YG: excitation approximately 480 nm, emission approximately 520 nm; BLUE: excitation approximately 590 nm, emission approximately 682 nm. Results are shown in the Table.

Table: Fluorescence Intensity of Background for Uncleared and Cleared Membranes

Background fluorescence intensity (arbitrary units)	YG	BLUE
Uncleared	1.287	0.119
Cleared	0.099	0.035

These results demonstrate the dramatic reduction in background signal in the cleared membrane.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention
5 described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

CLAIMS

What is claimed is:

- 5 1. A method of measuring the amount of an analyte of interest in a membrane, comprising the steps of:
 - a. applying to the membrane a clearing agent;
 - b. maintaining the membrane under conditions sufficient to allow clearing of the membrane; and
 - 10 c. measuring the amount of the analyte using an optical sensor.
- 15 2. The method of Claim 1, wherein the clearing agent is an agent that has approximately the same refractive index as the membrane.
3. The method of Claim 2, wherein the clearing agent is a polymer.
- 20 4. The method of Claim 2, wherein the clearing agent is a mixture of polymers.
5. The method of Claim 2, wherein the membrane is a nitrocellulose membrane.
- 25 6. The method of Claim 5, wherein the clearing agent is selected from the group consisting of:
polyvinylpyrrolidone, polyethyleneimine, and benzyl alcohol.
- 30 7. The method of Claim 1, wherein the clearing agent is a dissolving agent.
8. The method of Claim 7, wherein the dissolving agent is
35 a low molecular weight polymer.

-17-

9. The method of Claim 7, wherein the dissolving agent is a mixture of low molecular weight polymers.
- 5 10. The method of Claim 7, wherein the membrane is nitrocellulose.
11. The method of Claim 10, wherein the dissolving agent is a polyethylene glycol.
- 10 12. The method of Claim 1, wherein the analyte is labelled.
13. The method of Claim 12, wherein the label is a fluorescent label.
- 15 14. The method of Claim 13, wherein the optical sensor measures intensity of fluorescence.
- 20 15. The method of Claim 12, wherein the label is a detectable particle.
16. The method of Claim 15, wherein the detectable particle is fluorescently labeled.
- 25 17. The method of Claim 15, wherein the particle is a latex bead.
18. The method of Claim 15, wherein the optical sensor measures intensity of scattered light.
- 30

1/1




FIG. 1

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/543 G01N21/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 12, no. 53 (P-668), 18 February 1988 & JP 62 200244 A (NIPPON MASAHIKO COMPANY LTD), 3 September 1987, see abstract ---	1,2,5,7, 10,18
X	A. VACHEREAU: "Transparency of nitrocellulose membranes with Triton X-114." ELECTROPHORESIS, vol. 10, 1989, WEINHEIM FRG, pages 524-527, XP002053617 see the whole document --- -/-	1,2,5,7, 10,18

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 January 1998

Date of mailing of the international search report

13/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	<p>A.D. KLIMOV ET AL.: "Improved immunochromatographic format for competitive-type assays." CLINICAL CHEMISTRY, vol. 41, no. 9, 1995, WINSTON-SALEM NC USA, page 1360 XP002053450 cited in the application see the whole document -----</p>	1-18